Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Remote Monitoring in Young Adults With Inflammatory Joint Disease (ReMonit Young)

9 de novembro de 2026 atualizado por: Diakonhjemmet Hospital

Remote Monitoring and Personalized Patient Pathways in Young Adults With Inflammatory Joint Disease (ReMonit Young)

The goal of this clinical trial is to learn whether remote follow-up can work as well as regular in-person follow-up at the hospital for young adults with inflammatory joint diseases who have low disease activity. The study includes people aged 18 to 30 years with juvenile idiopathic arthritis, rheumatoid arthritis, psoriatic arthritis, or spondyloarthritis.

The main questions it aims to answer are:

  • Is remote follow-up non-inferior (not worse than) to regular in-person follow-up at the hospital in keeping participants' disease under good control over 24 months?
  • Is remote follow-up non-inferior to regular in-person follow-up when it comes to disease flare-ups, use of healthcare services, medication use, satisfaction with care, and safety? Researchers will compare a remote follow-up program, with fewer routine outpatient visits, to regular in-person follow-up to see whether disease control after 24 month is non-inferior (not worse)

Participants will:

  • Be randomly assigned to either remote digital follow-up or regular in-person follow-up at the hospital .
  • Complete questionnaires about their symptoms, health, and treatment during the study.
  • Attend appointments with a rheumatologist at the start of the study and at study end at 24 months.
  • If assigned to remote follow-up, complete questionnaires every 3 months using a smartphone or tablet application and communicate with a study nurse when needed through secure messaging in the remote monitoring software platform.
  • If assigned to regular in-person follow-up, attend routine appointments at the rheumatology clinic according to usual practice.

This study aims to determine whether remote follow-up can provide a safe and effective alternative to regular in-person follow-up for young adults with inflammatory joint diseases who have low disease activity .

Visão geral do estudo

Status

Ainda não está recrutando

Condições

Intervenção / Tratamento

Descrição detalhada

This project addresses follow-up care for young adults with an inflammatory joint disease (IJD), a group facing the challenge of the transition from pediatric to adult care and with variable treatment adherence. Remote digital follow-up may support timely detection of disease worsening, self-management, and efficient use of healthcare resources. However, there is limited evidence on whether remote follow-up is non-inferior to conventional in-person follow-up at the hospital in terms of disease control, particularly in this patient group .

The main objective is to assess whether a remote, digitally supported follow-up strategy is non-inferior to conventional scheduled in-person follow-up (outpatient care) regarding maintenance of low disease activity at 24 months in young adults (18-30 years) with juvenile idiopathic arthritis, rheumatoid arthritis, spondyloarthritis, or psoriatic arthritis who are in low disease activity and at a stable dosage of disease-modifying antirheumatic drug (DMARD) treatment.

Primary endpoint: Low disease activity at 24 months, defined by diagnosis-specific composite disease activity criteria. Non-inferiority is concluded if the lower bound of the two-sided 95% confidence interval for the difference (remote minus conventional) is above -15 percentage points.

Secondary endpoints include safety (disease flares, unscheduled visits due to worsening, adverse events, medication changes), patient satisfaction, medication adherence, composite disease activity scores, and inflammatory markers. Exploratory endpoints include healthcare costs and cost-effectiveness, travel-related carbon footprint of in-person consultations, user experience, and engagement with the digital platform.

Study design: A two-arm, parallel-group, open-label, non-inferiority study where participants are randomized 1:1 to remote digital follow-up or conventional in-person follow-up, stratified by diagnosis and medication-delivery mode (hospital-administered intravenous versus self-administered treatment). The statistician performing the primary analysis will be blinded to allocation. Duration of follow-up is 24 months. All participants continue their prescribed antirheumatic treatment.

Intervention: Remote follow-up using the MyDignio digital platform. Every three months, participants answer six triage questions on symptoms, adherence, side effects, treatment interruptions, impact on daily life, and need for a consultation with a health professional. Responses indicating increased symptoms, reduced adherence, side effects, treatment interruptions, or request for contact generate an alert. A study nurse then contacts the participant and arranges a telephone or in-person consultation within two weeks if needed. Participants can also send messages, which are reviewed 2-3 times/week. Scheduled contacts are rheumatologist consultations at baseline and 24 months and a nurse consultation at 12 months.

Conventional follow-up: Standard rheumatology in-patient follow-up care with rheumatologist assessments at baseline, 12, and 24 months and consultations with a nurse at 6 and 18 months. In both arms, additional consultations are arranged when clinically indicated, using the same criteria.

Tipo de estudo

Intervencional

Inscrição (Estimado)

148

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Locais de estudo

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos a 30 anos (Adulto)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  • Biological male or female aged 18-30 years at the time of informed consent
  • Clinical diagnosis of JIA, RA, SpA, or PsA
  • Stable DMARD treatment for ≥ 6 months; no initiation, discontinuation, or major dose escalation of a DMARD during the preceding 6 months. Temporary treatment interruptions and minor dose adjustments may be permitted.
  • Inactive disease or low disease activity at inclusion, according to diagnosis specific instrument thresholds (JADAS27≤2.7, DAS28≤ 3.2, ASDAS< 2.1, DAPSA≤14)
  • Ability to understand Norwegian
  • Capable of providing written informed consent
  • Access to a smartphone or tablet compatible with installation of the Dignio application

Exclusion Criteria:

Major co-morbidities, such as severe malignancies, severe diabetes mellitus, severe infections, uncontrollable hypertension, severe cardiovascular disease (NYHA class III or IV), severe respiratory diseases, and/or cirrhosis

  • Indications of active tuberculosis (TB)
  • Pregnant and/or breastfeeding
  • Stills disease (systemic JIA)
  • Currently enrolled in a different RCT
  • Abnormal renal function, defined as serum creatinine >142 µmol/L in female and >168 µmol/L in male, or glomerular filtration rate (GFR) <40 mL/min/1.73 m2
  • Abnormal liver function (defined as Alanine Transaminase (ALT) >3x upper normal limit), active or recent hepatitis
  • Leukopenia and/or thrombocytopenia
  • Severe psychiatric or mental disorders; current alcohol or other substance abuse; substantial language barriers; or any condition or circumstance that, in the investigator's judgment, would make adherence to the study protocol impossible.
  • Planned pregnancy during the study period.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Pesquisa de serviços de saúde
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Remote digital follow-up

Structured remote follow-up for 24 months using the MyDignio digital platform, with electronic triage questionnaires every three months, nurse review of alerts and messages, and scheduled consultations at baseline, 12 and 24 months. Participants continue their prescribed antirheumatic treatment.

Remote follow-up for 24 months using the MyDignio digital platform on the participant's smartphone or tablet, after training from the study team. Every three months, participants answer triage questions covering:

  • increased symptoms from their rheumatic disease
  • whether medication is taken as agreed with their rheumatologist
  • new medication side effects
  • recent interruptions in treatment
  • increased impact of symptoms on daily life
  • need for contact with a healthcare professional Any response indicating a potential problem generates an automatic alert, and the participant can describe the issue in free text. For each alert, a study nurse contacts the participant and, if needed, arranges a telephone or in-person consultation within two weeks. Participants may also send chat messages, which do not generate alert and are reviewed 2-3 times/week; the platform is not an emergency service.

Scheduled contacts: consultations with a rheumatologist at baseline and 24 months, and a consult

Comparador Ativo: Conventional hospital-based follow-up

Standard rheumatology outpatient follow-up for 24 months, with scheduled rheumatologist and nurse contacts at baseline, 6, 12, 18 and 24 months. Participants continue their prescribed antirheumatic treatment

Convetional rheumatology outpatient follow-up for 24 months, with rheumatologist in-person assessments at baseline, 12 and 24 months and consultations with a nurse, in-person or by telephone, at 6 and 18 months. Participants may contact the study nurse between scheduled visits, and additional consultations are arranged when clinically indicated, using the same criteria as in the remote arm. Participants continue their prescribed antirheumatic treatment.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Proportion of participants in low disease activity
Prazo: Baseline and 24 months

Assessed using a composite score specific to diagnosis. For all scores, higher values indicate higher disease activity. Participants are considered to be in low disease activity (including remission) if they meet the following criteria: JIA: Juvenile Arthritis Disease Activity Score 27 (JADAS27) ≤ 2.7; RA: Disease Activity Score 28 joints ≤3.2; SpA: Ankylosing Spondylitis Disease Activity Score <2.1; PsA: Disease Activity in Psoriatic Arthritis (DAPSA) ≤14.

Baseline and 24 months

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Number of participants with at least one disease flare
Prazo: 0-24 months

Number of participants with ≥1 disease flare. Flare is defined as: JIA: JADAS27 increase ≥1.7 from baseline and ≥1 active joint; RA: DAS28 increase ≥1.2 from baseline, or ≥0.6 if DAS28 ≥3.2; SpA: ASDAS increase ≥0.9 from baseline; PsA: DAPSA increase ≥7 from baseline; or, for all diagnoses, consensus between treating physician and participant that a clinically significant flare has occurred requiring intensified antirheumatic treatment. Assessed at scheduled and unscheduled visits.

0-24 months
Number of unscheduled rheumatology visits due to disease worsening
Prazo: 0-24 months

Number of unscheduled telephone or in-person rheumatology consultations due to worsening of the participant's inflammatory joint disease

0-24 months
Number and type of adverse events
Prazo: 12 and 24 months

Number and nature of adverse events and serious adverse events since the previous assessment

12 and 24 months
Number of participants with changes in anti-rheumatic medication
Prazo: 12 and 24 months

Number of participants with changes in antirheumatic treatment since the previous assessment

12 and 24 months
Number and type of medication-related side effects
Prazo: 12 and 24 months

Number and type of side effects attributed to medication since the previous assessment

12 and 24 months
Proportion of participants using NSAIDs and/or analgesics
Prazo: Baseline, 12, and 24 months

Proportion of participants reporting use of NSAIDS and/or analgesics

Baseline, 12, and 24 months
Number of antibiotic prescriptions dispensed
Prazo: 12 and 24 months

Number of antibiotic prescriptions dispensed to each participant since the previous assessment, obtained from the Norwegian Prescription Database

12 and 24 months
Overall satisfaction with care
Prazo: Baseline, 12, and 24 months

A single item from the Nordic Patient Experiences Questionnaire (NORPEQ) on overall satisfaction with care, rated on a five-point Likert scale from very satisfied to very dissatisfied, lower score indicates higher satisfaction

Baseline, 12, and 24 months
Medication adherence assessed with the MARS-5 questionnaire
Prazo: Baseline, 12, and 24 months

Self-reported adherence to anti-rheumatic medication measured with the Medication Adherence Report Scale-5 (MARS-5), consisting of five items each scored 1-5 (total range 5-25). Higher scores indicate greater adherence. Participants with a score ≥23 are classified as adherent.

Baseline, 12, and 24 months
Diagnosis-specific composite disease activity score
Prazo: Baseline, 12, and 24 months

Disease activity is assessed using a composite score specific to diagnosis (JADAS27 for JIA, DAS28 for RA, ASDAS for SpA and DAPSA for PsA). DAS28 assessed in addition to JADAS27 in participants with JIA. Higher scores indicate more disease activity.

Baseline, 12, and 24 months
C-reactive protein (CRP)
Prazo: Baseline, 12, and 24 months

CRP (mg/L), with higher values indicating more inflammation

Baseline, 12, and 24 months
Erythrocyte sedimentation rate (ESR)
Prazo: Baseline, 12, and 24 months

ESR (mm/h), with higher values indicating more inflammation

Baseline, 12, and 24 months

Outras medidas de resultado

Medida de resultado
Descrição da medida
Prazo
Patient-reported pain
Prazo: Baseline, 12, and 24 months

General pain last 7 days measured with a single item on a numeric rating scale (NRS) from 0 (no pain) to 10 (worst possible pain)

Baseline, 12, and 24 months
Patient-reported fatigue
Prazo: Baseline, 12, and 24 months

General fatigue last 7 days measured with a single item on a numeric rating scale (NRS) from 0 (no fatigue) to 10 (worst possible fatigue)

Baseline, 12, and 24 months
Patient global assessment of disease activity
Prazo: Baseline, 12, and 24 months

The patient global assessment of disease activity (last 7 days) component of the diagnosis-specific composite measure, standardized to NRS 0-10, with higher scores indicating more disease activity

Baseline, 12, and 24 months
Health-related quality of life as assessed by the EuroQol 5 Dimension 5 Level questionnaire
Prazo: Baseline, 12, and 24 months

Health-related quality of life measured with EuroQol Quality of Life 5 Dimensions 5 Level (EQ-5D-5L), covering mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Summarized as an index value with higher values indicating higher quality of life.

Baseline, 12, and 24 months
Self-reported overall health
Prazo: Baseline, 12, and 24 months

EuroQol single item. Reported on a visual analog scale 0-100, higher value indicates greater self-assessed overall health status

Baseline, 12, and 24 months
Impairment in non-work activities as assessed by the Work Productivity and Activity Impairment Questionnaire (WPAI)
Prazo: Baseline, 12, and 24 months

Item 6 of the Work Productivity and Activity Impairment questionnaire (WPAI) , converted to 0-100% impairment in non-work activities. Higher percentage indicates greater impairment.

Baseline, 12, and 24 months
Mental well-being as assessed by the WHO-5 Well-Being Index
Prazo: Baseline, 12, and 24 months

Self-reported mental well-being measured with the five-item WHO-5 Well-Being Index. Raw score 0-25, with higher scores indicating better wellbeing

Baseline, 12, and 24 months
Number of hospital contacts
Prazo: 0-24 months

Number of hospital contacts (outpatient visits and admissions), obtained from the Norwegian Patient Register

0-24 months
Number of dispensed prescriptions of anti-rheumatic medication
Prazo: 0-24 months

Number and type of anti-rheumatic medication prescriptions dispensed, obtained from the Norwegian Prescription Database (NorPD)[N

0-24 months
Number of primary care contacts
Prazo: 0-24 months

Number of contacts with primary care (e.g. general practitioner and emergency primary care), obtained from the Control and Payment of Health Reimbursements (KUHR) database

0-24 months
Costs related to hospital visits
Prazo: Baseline

Self-reported travel distance in kilometers to the hospital.

Baseline
Costs related to hospital visits
Prazo: Baseline

Self-reported way of transport to the hospital; walking or bicycling/private car/public transportation/taxi/airplane/other.

Baseline
Proportion of participants in paid work who need to take time off work for rheumatology consultations
Prazo: Baseline

Participants in paid work report whether they need to take time off work to attend rheumatology consultations at the hospital, whether in person, by telephone, or by video (yes/no). Participants who are not in paid work are not asked to answer this item.

Baseline
Incremental cost-effectiveness ratio
Prazo: 0-24 months

Within-trial cost-utility analysis. Quality-adjusted life years (QALYs) estimated from EQ-5D-5L, results presented as incremental cost per QALY gained

0-24 months
Patient satisfaction with remote monitoring
Prazo: 12 and 24 months

Service User Technology Acceptability Questionnaire (SUTAQ) reported by the Remote monitoring group. 22 items in 5 subscales. Score range 1-6. Higher scores in subscales 1,2 and 5/lower scores in subscales 3 and 4 indicate higher acceptability with telehealth.

12 and 24 months
Completion of scheduled triage questionnaire and use of the digital platform
Prazo: 3-21 months

Proportion of scheduled triage questionnaires (3, 6, 9, 12, 15, 18 and 21 months) completed, and patterns of interaction with the MyDignio platform. Asessed in the remote follow-up group only

3-21 months
Number of withdrawals or early discontinuation
Prazo: 0-24 months

Number of withdrawals/early discontinuation

0-24 months
Patient-reported self-efficacy for using different digital devices, secure login and digital health services
Prazo: Baseline

Self-efficacy/confidence in using smartphone, tablet, computer, app's, secure login and digital health services. 6 items with Likert scale response categories: Never used, Very bad, Bad, Neither good nor bad, Good, Very good. Score range 0-5; higher scores indicate higher self-efficacy.

Baseline
eHealth literacy
Prazo: Baseline

20 items from 4 domains of the eHealth Literacy Questionnaire (eHLQ). Four-point response scale, sum domain score range 1-4. Lower scores indicate lower eHealth literacy.

Baseline
Travel-related carbon footprint of in-person consultations
Prazo: 0-24 months

Estimated greenhouse gas emissions (kg CO2-equivalents per participant) from travel to and from in-person rheumatology consultations. Calculated from the number of in-person consultations, self-reported travel distance and usual mode of transport, and emission factors per passenger-kilometre.

0-24 months

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Estimado)

1 de dezembro de 2026

Conclusão Primária (Estimado)

1 de dezembro de 2029

Conclusão do estudo (Estimado)

1 de dezembro de 2029

Datas de inscrição no estudo

Enviado pela primeira vez

9 de novembro de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

9 de novembro de 2026

Primeira postagem (Real)

16 de novembro de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

16 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

9 de novembro de 2026

Última verificação

1 de novembro de 2026

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • DS-26/00970
  • 2025064 (Número de outro subsídio/financiamento: South-Eastern Norway Regional Health Authority)

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

NÃO

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .